Michael Messig
Overview
Explore the profile of Michael Messig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arnold L, Arsenault P, Huffman C, Patrick J, Messig M, Chew M, et al.
Curr Med Res Opin
. 2017 Mar;
33(4):795-796.
PMID: 28276874
No abstract available.
2.
Shepherd J, Breazna A, Deedwania P, LaRosa J, Wenger N, Messig M, et al.
Am J Cardiol
. 2016 Mar;
117(8):1199-205.
PMID: 26940556
Statins may have nephroprotective as well as cardioprotective effects in patients with cardiovascular disease. In the Treating to New Targets (TNT) study (NCT00327691), patients with coronary heart disease (CHD) were...
3.
Black D, Messig M, Yu C, Assaf A, Komm B, Mirkin S, et al.
Menopause
. 2015 Dec;
23(4):376-82.
PMID: 26694733
Objective: This post hoc analysis compared body weight, body mass index (BMI), and BMI category changes in postmenopausal women treated with conjugated estrogens/bazedoxifene (CE/BZA) versus placebo in the Selective Estrogens,...
4.
Ninan P, Musgnung J, Messig M, Buckley G, Guico-Pabia C, Ramey T
Prim Care Companion CNS Disord
. 2015 Jul;
17(1).
PMID: 26137358
Objective: The purpose of this post hoc analysis was to evaluate the incidence and timing of taper/posttherapy-emergent adverse events (TPAEs) following discontinuation of long-term treatment with desvenlafaxine (administered as desvenlafaxine...
5.
Kohli P, Waters D, Nemr R, Arsenault B, Messig M, DeMicco D, et al.
J Am Coll Cardiol
. 2015 Jan;
65(4):402-404.
PMID: 25634843
No abstract available.
6.
Amarenco P, Callahan 3rd A, Campese V, Goldstein L, Hennerici M, Messig M, et al.
Stroke
. 2014 Aug;
45(10):2974-82.
PMID: 25147328
Background And Purpose: Higher low-density lipoprotein cholesterol is associated with more rapid chronic kidney disease progression; reduction in cholesterol with statins, in conjunction with statins' pleiotropic effects, such as decreasing...
7.
Arnold L, Arsenault P, Huffman C, Patrick J, Messig M, Chew M, et al.
Curr Med Res Opin
. 2014 May;
30(10):2069-83.
PMID: 24867298
Objective: Safety and efficacy of a once daily controlled-released (CR) formulation of pregabalin was evaluated in patients with fibromyalgia using a placebo-controlled, randomized withdrawal design. Research Design And Methods: This...
8.
Abraham L, Pinkerton J, Messig M, Ryan K, Komm B, Mirkin S
Maturitas
. 2014 May;
78(3):212-8.
PMID: 24837362
Objective: Describe the effects of conjugated estrogens/bazedoxifene (CE/BZA), a new treatment for vasomotor symptoms (VMS) and osteoporosis prevention, on menopause-specific quality of life (MSQOL) across different patient population types in...
9.
Khan A, Musgnung J, Ramey T, Messig M, Buckley G, Ninan P
J Clin Psychopharmacol
. 2014 Apr;
34(3):365-8.
PMID: 24717247
The objective of this study was to determine whether the occurrence of discontinuation symptoms was equivalent for abrupt discontinuation versus 1-week taper to desvenlafaxine 25 mg/d after a 24-week treatment...
10.
Ong K, Waters D, Messig M, DeMicco D, Rye K, Barter P
Am J Cardiol
. 2014 Mar;
113(10):1593-8.
PMID: 24666618
Features of the metabolic syndrome are independent risk factors for new-onset diabetes mellitus (NODM) related to statin therapy. Obesity is the predominant underlying risk factor for the metabolic syndrome and...